Gyre Therapeutics has completed its acquisition of Cullgen in an all-stock deal valued at about $300 million, forming a fully integrated biopharmaceutical company based in the US and China. The combined company now offers a commercial product, ETUARY®, for lung fibrosis in China, and a robust pipeline including treatments for liver fibrosis and inflammatory diseases. Leadership changes include Dr. Ying Luo becoming CEO and President, with Ping Zhang remaining Chairman. The acquisition strengthens Gyre's position with innovative targeted protein degrader therapies and supports future global growth, with ongoing clinical trials and regulatory progress in China and plans for expansion outside China, including the US.
FREELANDER International has revealed the dimensions of its first strategic model, the FREELANDER 8, a mid-to-large size SUV measuring 5,118 mm long, 2,050 mm wide, and 1,926 mm high. The vehicle combines British craftsmanship, intelligent technology...
Yorkville International Capital Corp. priced its initial public offering at $200 million, selling 20 million units at $10 each. The units will trade on Nasdaq's Global Market under the ticker YICCU starting June 16, 2026, with each unit comprising on...
Pepeto's presale has raised over $10.27 million and is preparing for a Binance listing amid a forming crypto bull run, promising strong potential gains similar to past Binance token launches. Meanwhile, Standard Chartered predicts XRP could reach $8 ...
Ready Capital Corporation announced quarterly cash dividends for Q2 2026. Common stockholders and Operating Partnership unit holders will receive $0.01 per share payable on July 31, 2026. Additionally, dividends of $0.390625 per share for Series C Pr...
Terra Innovatum Global filed its 2025 Annual Report on Form 10-K, marking its first full year as a public company. The company ended fiscal 2025 with $102.9 million in cash and no debt, supported by proceeds from its business combination with GSR III...
